Twelve hundred ninety-six patients with resected colon cancer that either was locally invasive (Stage B2) or had regional nodal involvement (Stage C) were randomly assigned to observation or to treatment for one year with levamisole combined with fluorouracil. Patients with Stage C disease could also be randomly assigned to treatment with levamisole alone. The median follow-up time at this writing is 3 years (range, 2 to 5 1/2). Among the patients with Stage C disease, therapy with levamisole plus fluorouracil reduced the risk of cancer recurrence by 41 percent (P less than 0.0001). The overall death rate was reduced by 33 percent (P approximately 0.006). Treatment with levamisole alone had no detectable effect. The results in the patients with Stage B2 disease were equivocal and too preliminary to allow firm conclusions. Toxic effects of levamisole alone were infrequent, usually consisting of mild nausea with occasional dermatitis or leukopenia, and those of levamisole plus fluorouracil were essentially the same as those of fluorouracil alone--i.e., nausea, vomiting, stomatitis, diarrhea, dermatitis, and leukopenia. These reactions were usually not severe and did not greatly impede patients' compliance with their regimen. We conclude that adjuvant therapy with levamisole and fluorouracil should be standard treatment for Stage C colon carcinoma. Since most patients in our study were treated by community oncologists, this approach should be readily adaptable to conventional medical practice.
Source Information
Mayo Clinic, Rochester, MN 55905.
This article has been cited by other articles:
Carethers, J. M.
(2008). Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor. Therapeutic Advances in Gastroenterology
1: 33-42
[Abstract]
Zlobec, I., Terracciano, L. M., Lugli, A.
(2008). Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes. Clin. Cancer Res.
14: 3792-3797
[Abstract][Full Text]
Keating, N. L., Landrum, M. B., Klabunde, C. N., Fletcher, R. H., Rogers, S. O., Doucette, W. R., Tisnado, D., Clauser, S., Kahn, K. L.
(2008). Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity?. JCO
26: 2532-2537
[Abstract][Full Text]
Fleming, T. R, Sharples, K., McCall, J., Moore, A., Rodgers, A., Stewart, R.
(2008). Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials
5: 157-167
[Abstract]
Bradley, C. J., Given, C. W., Dahman, B., Fitzgerald, T. L.
(2008). Adjuvant Chemotherapy After Resection in Elderly Medicare and Medicaid Patients With Colon Cancer. Arch Intern Med
168: 521-529
[Abstract][Full Text]
Berglund, A., Cedermark, B., Glimelius, B.
(2008). Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?. Ann Oncol
19: 400-402
[Full Text]
Grothey, A.
(2007). Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?. Clin. Cancer Res.
13: 6909s-6912s
[Abstract][Full Text]
Nicastri, D. G., Doucette, J. T., Godfrey, T. E., Hughes, S. J.
(2007). Is Occult Lymph Node Disease in Colorectal Cancer Patients Clinically Significant?: A Review of the Relevant Literature. J. Mol. Diagn.
9: 563-571
[Abstract][Full Text]
Sargent, D. J., Patiyil, S., Yothers, G., Haller, D. G., Gray, R., Benedetti, J., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., Grothey, A., O'Connell, M., Catalano, P. J., Kerr, D., Green, E., Wieand, H. S., Goldberg, R. M., de Gramont, A.
(2007). End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. JCO
25: 4569-4574
[Abstract][Full Text]
Sezeur, A., Chatelet, F.P., Cywiner, Ch., de Labriolle-Vaylet, Cl., Chastang, C., Billotey, Cl., Malafosse, M., Gallot, D., Betton, P., Montravers, F., Carvajal-Gonzalez, S., Askienazy, S., Talbot, J.N., Rain, J.D., Milhaud, G., Saumon, G., Barbet, J., Gruaz-Guyon, A.
(2007). Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging. Clin. Cancer Res.
13: 5592s-5597s
[Abstract][Full Text]
Andre, T., Quinaux, E., Louvet, C., Colin, P., Gamelin, E., Bouche, O., Achille, E., Piedbois, P., Tubiana-Mathieu, N., Boutan-Laroze, A., Flesch, M., Lledo, G., Raoul, Y., Debrix, I., Buyse, M., de Gramont, A.
(2007). Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1. JCO
25: 3732-3738
[Abstract][Full Text]
Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., Fields, A. L.A., Mayer, R. J.
(2007). Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. JCO
25: 3456-3461
[Abstract][Full Text]
Bottarelli, L., Azzoni, C., Necchi, F., Lagrasta, C., Tamburini, E., D'Adda, T., Pizzi, S., Sarli, L., Rindi, G., Bordi, C.
(2007). Sex Chromosome Alterations Associate with Tumor Progression in Sporadic Colorectal Carcinomas. Clin. Cancer Res.
13: 4365-4370
[Abstract][Full Text]
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., Zapas, J. L., Goodwin, J. W., Fehrenbacher, L., Ramanathan, R. K., Conley, B. A., Flynn, P. J., Soori, G., Colman, L. K., Levine, E. A., Lanier, K. S., Wolmark, N.
(2007). Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07. JCO
25: 2198-2204
[Abstract][Full Text]
Muss, H. B., Biganzoli, L., Sargent, D. J., Aapro, M.
(2007). Adjuvant Therapy in the Elderly: Making the Right Decision. JCO
25: 1870-1875
[Abstract][Full Text]
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., Mayer, R. J.
(2007). Adjuvant Treatment of Colorectal Cancer. CA Cancer J Clin
57: 168-185
[Abstract][Full Text]
Shen, Y., Cheng, Y.
(2007). Adaptive design: estimation and inference with censored data in a semiparametric model. Biostatistics
8: 306-322
[Abstract][Full Text]
Lin, C-H, Jeng, J-S, Hsieh, S-T, Yip, P-K, Wu, R-M
(2007). Acute disseminated encephalomyelitis: a follow-up study in Taiwan. J. Neurol. Neurosurg. Psychiatry
78: 162-167
[Abstract][Full Text]
White, M J, O'Gorman, R L, Charles-Edwards, E M, Kane, P A, Karani, J B, Leach, M O, Totman, J J
(2007). Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br. J. Radiol.
80: 113-120
[Abstract][Full Text]
Lemmens, V., van Lijnschoten, I, Janssen-Heijnen, M., Rutten, H., Verheij, C., Coebergh, J-W.
(2006). Pathology practice patterns affect lymph node evaluation and outcome of colon cancer: a population-based study. Ann Oncol
17: 1803-1809
[Abstract][Full Text]
Chau, I, Cunningham, D
(2006). Adjuvant therapy in colon cancer--what, when and how?. Ann Oncol
17: 1347-1359
[Abstract][Full Text]
Smalley, S. R., Benedetti, J. K., Williamson, S. K., Robertson, J. M., Estes, N. C., Maher, T., Fisher, B., Rich, T. A., Martenson, J. A., Kugler, J. W., Benson, A. B. III, Haller, D. G., Mayer, R. J., Atkins, J. N., Cripps, C., Pedersen, J., Periman, P. O., Tanaka, M. S. Jr, Leichman, C. G., Macdonald, J. S.
(2006). Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144. JCO
24: 3542-3547
[Abstract][Full Text]
Monga, D. K., O'Connell, M. J.
(2006). Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions. Ann. Surg. Oncol.
13: 1021-1034
[Abstract][Full Text]
Andre, T., Sargent, D., Tabernero, J., O'Connell, M., Buyse, M., Sobrero, A., Misset, J.-L., Boni, C., de Gramont, A.
(2006). Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Ann. Surg. Oncol.
13: 887-898
[Abstract][Full Text]
Carethers, J M
(2006). Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.. Gut
55: 759-761
[Full Text]
Jover, R, Zapater, P, Castells, A, Llor, X, Andreu, M, Cubiella, J, Pinol, V, Xicola, R M, Bujanda, L, Rene, J M, Clofent, J, Bessa, X, Morillas, J D, Nicolas-Perez, D, Paya, A, Alenda, C, for the Gastrointestinal Oncology Group of the Spa,
(2006). Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut
55: 848-855
[Abstract][Full Text]
Grann, V. R., Muggia, F. M.
(2006). Completion rates of adjuvant chemotherapy for colon cancer: a historical perspective.. JNCI J Natl Cancer Inst
98: 570-571
[Full Text]
Dobie, S. A., Baldwin, L.-M., Dominitz, J. A., Matthews, B., Billingsley, K., Barlow, W.
(2006). Completion of therapy by Medicare patients with stage III colon cancer.. JNCI J Natl Cancer Inst
98: 610-619
[Abstract][Full Text]
Haydon, A M M, MacInnis, R J, English, D R, Giles, G G
(2006). Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut
55: 62-67
[Abstract][Full Text]
Bilchik, A. J., Poston, G., Curley, S. A., Strasberg, S., Saltz, L., Adam, R., Nordlinger, B., Rougier, P., Rosen, L. S.
(2005). Neoadjuvant Chemotherapy for Metastatic Colon Cancer: A Cautionary Note. JCO
23: 9073-9078
[Full Text]
Jessup, J. M., Stewart, A., Greene, F. L., Minsky, B. D.
(2005). Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Race/Ethnicity, Age, and Differentiation. JAMA
294: 2703-2711
[Abstract][Full Text]
Van Cutsem, E., Costa, F.
(2005). Progress in the Adjuvant Treatment of Colon Cancer: Has It Influenced Clinical Practice?. JAMA
294: 2758-2760
[Full Text]
Haller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., Mayer, R. J.
(2005). Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089. JCO
23: 8671-8678
[Abstract][Full Text]
Douillard, J. Y., Bennouna, J.
(2005). Adjuvant chemotherapy for colon cancer: a confusing area!. Ann Oncol
16: 1853-1854
[Full Text]
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., Grothey, A., O'Connell, M., Catalano, P. J., Blanke, C. D., Kerr, D., Green, E., Wolmark, N., Andre, T., Goldberg, R. M., De Gramont, A.
(2005). Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. JCO
23: 8664-8670
[Abstract][Full Text]
Chua, Y. J., Sargent, D., Cunningham, D.
(2005). Definition of disease-free survival: this is my truth-show me yours. Ann Oncol
16: 1719-1721
[Full Text]
Edwards, B. K., Brown, M. L., Wingo, P. A., Howe, H. L., Ward, E., Ries, L. A. G., Schrag, D., Jamison, P. M., Jemal, A., Wu, X. C., Friedman, C., Harlan, L., Warren, J., Anderson, R. N., Pickle, L. W.
(2005). Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment. JNCI J Natl Cancer Inst
97: 1407-1427
[Abstract][Full Text]
Lee, J., Lee, K.-E., Im, Y.-H., Kang, W. K., Park, K., Kim, K., Shim, Y. M.
(2005). Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma. Ann. Thorac. Surg.
80: 1170-1175
[Abstract][Full Text]
de Gramont, A.
(2005). Rapid Evolution in Colorectal Cancer: Therapy Now and Over the Next Five Years. The Oncologist
10: 4-8
[Abstract][Full Text]
Wong, J. H., Johnson, D. S., Hemmings, D., Hsu, A., Imai, T., Tominaga, G. T.
(2005). Assessing the Quality of Colorectal Cancer Staging: Documenting the Process in Improving the Staging of Node-Negative Colorectal Cancer. Arch Surg
140: 881-887
[Abstract][Full Text]
Alhopuro, P., Alazzouzi, H., Sammalkorpi, H., Davalos, V., Salovaara, R., Hemminki, A., Jarvinen, H., Mecklin, J.-P., Schwartz, S. Jr., Aaltonen, L. A., Arango, D.
(2005). SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer. Clin. Cancer Res.
11: 6311-6316
[Abstract][Full Text]
Ohrling, K., Edler, D., Hallstrom, M., Ragnhammar, P., Blomgren, H.
(2005). Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information. JCO
23: 5628-5634
[Abstract][Full Text]
Ioannidis, J. P. A.
(2005). Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. JAMA
294: 218-228
[Abstract][Full Text]
Allegra, C., Sargent, D. J.
(2005). Adjuvant Therapy for Colon Cancer -- The Pace Quickens. NEJM
352: 2746-2748
[Full Text]
Grothey, A., Sargent, D. J.
(2005). FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer. JCO
23: 3311-3313
[Full Text]
Lemmens, V. E. P. P., van Halteren, A. H., Janssen-Heijnen, M. L. G., Vreugdenhil, G., Repelaer van Driel, O. J., Coebergh, J. W. W.
(2005). Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol
16: 767-772
[Abstract][Full Text]
Baddi, L., Benson, A. III
(2005). Adjuvant Therapy in Stage II Colon Cancer: Current Approaches. The Oncologist
10: 325-331
[Full Text]
Popat, S., Wort, R., Houlston, R. S.
(2005). Relationship Between Thymidylate Synthase (TS) Genotype and TS Expression: A Tissue Microarray Analysis of Colorectal Cancers. INT J SURG PATHOL
13: 127-133
[Abstract]
Sobrero, A., Sciallero, S.
(2005). Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months?. Ann Oncol
16: 521-522
[Full Text]
Alazzouzi, H., Alhopuro, P., Salovaara, R., Sammalkorpi, H., Jarvinen, H., Mecklin, J.-P., Hemminki, A., Schwartz, S. Jr., Aaltonen, L. A., Arango, D.
(2005). SMAD4 as a Prognostic Marker in Colorectal Cancer. Clin. Cancer Res.
11: 2606-2611
[Abstract][Full Text]
Poplin, E. A., Benedetti, J. K., Estes, N. C., Haller, D. G., Mayer, R. J., Goldberg, R. M., Weiss, G. R., Rivkin, S. E., Macdonald, J. S.
(2005). Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer. JCO
23: 1819-1825
[Abstract][Full Text]
Delaunoit, T., Alberts, S. R., Sargent, D. J., Green, E., Goldberg, R. M., Krook, J., Fuchs, C., Ramanathan, R. K., Williamson, S. K., Morton, R. F., Findlay, B. P.
(2005). Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol
16: 425-429
[Abstract][Full Text]
Yao, M., Zhou, W., Sangha, S., Albert, A., Chang, A. J., Liu, T. C., Wolfe, M. M.
(2005). Effects of Nonselective Cyclooxygenase Inhibition with Low-Dose Ibuprofen on Tumor Growth, Angiogenesis, Metastasis, and Survival in a Mouse Model of Colorectal Cancer. Clin. Cancer Res.
11: 1618-1628
[Abstract][Full Text]
Popat, S., Hubner, R., Houlston, R.S.
(2005). Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis. JCO
23: 609-618
[Abstract][Full Text]
Sadahiro, S., Suzuki, T., Ishikawa, K., Nakamura, T., Tanaka, Y., Ishizu, K., Yasuda, S., Makuuchi, H., Murayama, C.
(2005). Estimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis. Jpn J Clin Oncol
35: 18-22
[Abstract][Full Text]
Porta-Oltra, B, Perez-Ruixo, J., Climente-Marti, M, Merino-Sanjuan, M, Almenar-Cubells, D, Jimenez-Torres, N.
(2004). Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients. J Oncol Pharm Pract
10: 155-167
[Abstract]
Benson, A. B. III, Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., Brouwers, M., Charette, M., Haller, D. G.
(2004). American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. JCO
22: 3408-3419
[Abstract][Full Text]
Martenson, J. A. Jr, Willett, C. G., Sargent, D. J., Mailliard, J. A., Donohue, J. H., Gunderson, L. L., Thomas, C. R. Jr, Fisher, B., Benson, A. B. III, Myerson, R., Goldberg, R. M.
(2004). Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130. JCO
22: 3277-3283
[Abstract][Full Text]
Smith, R. E., Colangelo, L., Wieand, H. S., Begovic, M., Wolmark, N.
(2004). Randomized Trial of Adjuvant Therapy in Colon Carcinoma: 10-Year Results of NSABP Protocol C-01. JNCI J Natl Cancer Inst
96: 1128-1132
[Abstract][Full Text]
Slevin, M., Payne, S.
(2004). New treatments for colon cancer. BMJ
329: 124-126
[Full Text]
Andre, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., Tabah-Fisch, I., de Gramont, A., the Multicenter International Study of Oxaliplatin,
(2004). Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. NEJM
350: 2343-2351
[Abstract][Full Text]
Gunderson, L. L., Sargent, D. J., Tepper, J. E., Wolmark, N., O'Connell, M. J., Begovic, M., Allmer, C., Colangelo, L., Smalley, S. R., Haller, D. G., Martenson, J. A., Mayer, R. J., Rich, T. A., Ajani, J. A., MacDonald, J. S., Willett, C. G., Goldberg, R. M.
(2004). Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer: A Pooled Analysis. JCO
22: 1785-1796
[Abstract][Full Text]
Gill, S., Loprinzi, C. L., Sargent, D. J., Thome, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., Labianca, R., Chen, W., Cha, S. S., Heldebrant, M. P., Goldberg, R. M.
(2004). Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. JCO
22: 1797-1806
[Abstract][Full Text]
Garrity, M. M., Burgart, L. J., Mahoney, M. R., Windschitl, H. E., Salim, M., Wiesenfeld, M., Krook, J. E., Michalak, J. C., Goldberg, R. M., O'Connell, M. J., Furth, A. F., Sargent, D. J., Murphy, L. M., Hill, E., Riehle, D. L., Meyers, C. H., Witzig, T. E.
(2004). Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study. JCO
22: 1572-1582
[Abstract][Full Text]
Kruskal, J. B., Thomas, P., Kane, R. A., Goldberg, S. N.
(2004). Hepatic Perfusion Changes in Mice Livers with Developing Colorectal Cancer Metastases. Radiology
231: 482-490
[Abstract][Full Text]
Parc, Y, Gueroult, S, Mourra, N, Serfaty, L, Flejou, J-F, Tiret, E, Parc, R
(2004). Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut
53: 371-375
[Abstract][Full Text]
(2004). Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials. JCO
22: 484-492
[Abstract][Full Text]
Scher, H. I., Eisenberger, M., D'Amico, A. V., Halabi, S., Small, E. J., Morris, M., Kattan, M. W., Roach, M., Kantoff, P., Pienta, K. J., Carducci, M. A., Agus, D., Slovin, S. F., Heller, G., Kelly, W. K., Lange, P. H., Petrylak, D., Berg, W., Higano, C., Wilding, G., Moul, J. W., Partin, A. N., Logothetis, C., Soule, H. R.
(2004). Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group. JCO
22: 537-556
[Abstract][Full Text]
Mariadason, J. M., Arango, D., Shi, Q., Wilson, A. J., Corner, G. A., Nicholas, C., Aranes, M. J., Lesser, M., Schwartz, E. L., Augenlicht, L. H.
(2003). Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin. Cancer Res.
63: 8791-8812
[Abstract][Full Text]
Rice, T. W., Adelstein, D. J., Chidel, M. A., Rybicki, L. A., DeCamp, M. M., Murthy, S. C., Blackstone, E. H.
(2003). Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J. Thorac. Cardiovasc. Surg.
126: 1590-1596
[Abstract][Full Text]
Ward, R. L., Cheong, K., Ku, S.-L., Meagher, A., O'Connor, T., Hawkins, N. J.
(2003). Adverse Prognostic Effect of Methylation in Colorectal Cancer Is Reversed by Microsatellite Instability. JCO
21: 3729-3736
[Abstract][Full Text]
Wright, F.C., Law, C.H. L., Last, L., Khalifa, M., Arnaout, A., Naseer, Z., Klar, N., Gallinger, S., Smith, A.J.
(2003). Lymph Node Retrieval and Assessment in Stage II Colorectal Cancer: A Population-Based Study. Ann. Surg. Oncol.
10: 903-909
[Abstract][Full Text]
Di Costanzo, F., Sobrero, A., Gasperoni, S., Dogliotti, L., Frassineti, L., Falcone, A., Lionetto, R., Bruzzi, P., Luppi, G., Gallo, L., Conte, P., Comandone, A., Turci, D., Marzola, M., Folco, U., Pfanner, E., Mestriner, M., Boni, C., Galli, C., Tonato, M., Rosso, R.
(2003). Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol
14: 1365-1372
[Abstract][Full Text]
Andre, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O., Achille, E., Colbert, N., Boaziz, C., Piedbois, P., Tubiana-Mathieu, N., Boutan-Laroze, A., Flesch, M., Buyse, M., de Gramont, A.
(2003). Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial. JCO
21: 2896-2903
[Abstract][Full Text]
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., Tu, D., Redston, M., Gallinger, S.
(2003). Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. NEJM
349: 247-257
[Abstract][Full Text]
Ayanian, J. Z., Zaslavsky, A. M., Fuchs, C. S., Guadagnoli, E., Creech, C. M., Cress, R. D., O'Connor, L. C., West, D. W., Allen, M. E., Wolf, R. E., Wright, W. E.
(2003). Use of Adjuvant Chemotherapy and Radiation Therapy for Colorectal Cancer in a Population-Based Cohort. JCO
21: 1293-1300
[Abstract][Full Text]
Arkenau, H. T., Bermann, A., Rettig, K., Strohmeyer, G., Porschen, R.
(2003). 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol
14: 395-399
[Abstract][Full Text]
Earle, C. C., Grunfeld, E., Coyle, D., Cripps, M. C., Stern, H. S.
(2003). Cancer physicians' attitudes toward colorectal cancer follow-up. Ann Oncol
14: 400-405
[Abstract][Full Text]
Yao, M., Kargman, S., Lam, E. C., Kelly, C. R., Zheng, Y., Luk, P., Kwong, E., Evans, J. F., Wolfe, M. M.
(2003). Inhibition of Cyclooxygenase-2 by Rofecoxib Attenuates the Growth and Metastatic Potential of Colorectal Carcinoma in Mice. Cancer Res.
63: 586-592
[Abstract][Full Text]
Desai, D. C., Zervos, E. E., Arnold, M. W., Burak, W. E. Jr., Mantil, J., Martin, E. W. Jr.
(2003). Positron Emission Tomography Affects Surgical Management in Recurrent Colorectal Cancer Patients. Ann. Surg. Oncol.
10: 59-64
[Abstract][Full Text]
Chau, I., Cunningham, D.
(2002). Chemotherapy in colorectal cancer: new options and new challenges. Br Med Bull
64: 159-180
[Abstract][Full Text]
Schrag, D., Rifas-Shiman, S., Saltz, L., Bach, P. B., Begg, C. B.
(2002). Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer. JCO
20: 3999-4005
[Abstract][Full Text]
Iacopetta, B.
(2002). A biological perspective on the selection of stage II colorectal cancer patients for adjuvant chemotherapy. Ann Oncol
13: 1510-1510
[Full Text]
Faivre-Finn, C, Bouvier-Benhamiche, A-M, Phelip, J M, Manfredi, S, Dancourt, V, Faivre, J
(2002). Colon cancer in France: evidence for improvement in management and survival. Gut
51: 60-64
[Abstract][Full Text]
Petersen, V C, Baxter, K J, Love, S B, Shepherd, N A
(2002). Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut
51: 65-69
[Abstract][Full Text]
Choi, S.-W., Lee, K. J., Bae, Y.-A., Min, K.-O., Kwon, M.-S., Kim, K.-M., Rhyu, M.-G.
(2002). Genetic Classification of Colorectal Cancer Based on Chromosomal Loss and Microsatellite Instability Predicts Survival. Clin. Cancer Res.
8: 2311-2322
[Abstract][Full Text]
Neugut, A. I., Fleischauer, A. T., Sundararajan, V., Mitra, N., Heitjan, D. F., Jacobson, J. S., Grann, V. R.
(2002). Use of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study. JCO
20: 2643-2650
[Abstract][Full Text]
Edler, D., Glimelius, B., Hallstrom, M., Jakobsen, A., Johnston, P. G., Magnusson, I., Ragnhammar, P., Blomgren, H.
(2002). Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based Chemotherapy. JCO
20: 1721-1728
[Abstract][Full Text]
Allegra, C. J., Parr, A. L., Wold, L. E., Mahoney, M. R., Sargent, D. J., Johnston, P., Klein, P., Behan, K., O'Connell, M. J., Levitt, R., Kugler, J. W., Tria Tirona, M., Goldberg, R. M.
(2002). Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer. JCO
20: 1735-1743
[Abstract][Full Text]
Tepper, J.E., O'Connell, M., Niedzwiecki, D., Hollis, D.R., Benson, A.B. III, Cummings, B., Gunderson, L.L., Macdonald, J.S., Martenson, J.A., Mayer, R.J.
(2002). Adjuvant Therapy in Rectal Cancer: Analysis of Stage, Sex, and Local Control--Final Report of Intergroup 0114. JCO
20: 1744-1750
[Abstract][Full Text]
Sundararajan, V., Mitra, N., Jacobson, J. S., Grann, V. R., Heitjan, D. F., Neugut, A. I.
(2002). Survival Associated with 5-Fluorouracil-Based Adjuvant Chemotherapy among Elderly Patients with Node-Positive Colon Cancer. ANN INTERN MED
136: 349-357
[Abstract][Full Text]
Litvak, D. A., Wood, T. F., Tsioulias, G. J., Chung, M., Chawla, S. P., Foshag, L. J., Morton, D. L., Ramming, K. P., Bilchik, A. J.
(2002). Systemic Irinotecan and Regional Floxuridine After Hepatic Cytoreduction in 185 Patients With Unresectable Colorectal Cancer Metastases. Ann. Surg. Oncol.
9: 148-155
[Abstract][Full Text]
Taylor, W. E., Donohue, J. H., Gunderson, L. L., Nelson, H., Nagorney, D. M., Devine, R. M., Haddock, M. G., Larson, D. R., Rubin, J., O'Connell, M. J.
(2002). The Mayo Clinic Experience With Multimodality Treatment of Locally Advanced or Recurrent Colon Cancer. Ann. Surg. Oncol.
9: 177-185
[Abstract][Full Text]
Potosky, A. L., Harlan, L. C., Kaplan, R. S., Johnson, K. A., Lynch, C. F.
(2002). Age, Sex, and Racial Differences in the Use of Standard Adjuvant Therapy for Colorectal Cancer. JCO
20: 1192-1202
[Abstract][Full Text]
Bepler, G., Gautam, A., McIntyre, L. M., Beck, A. F., Chervinsky, D. S., Kim, Y.-C., Pitterle, D. M., Hyland, A.
(2002). Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Non-Small-Cell Lung Cancer. JCO
20: 1353-1360
[Abstract][Full Text]
Summerhayes, M.
(2001). Capecitabine: a novel, orally administered, tumour-activated treatment for colorectal cancer. J Oncol Pharm Pract
7: 107-125
[Abstract]
Wolff, R. A.
(2001). Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas: Great Logic, Grim Reality. Ann. Surg. Oncol.
8: 747-748
[Full Text]
Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., Francini, G.
(2001). A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients. NEJM
345: 1091-1097
[Abstract][Full Text]
Meterissian, S. H., Kontogiannea, M., Al-Sowaidi, M., Linjawi, A., Halwani, F., Jamison, B., Edwardes, M.
(2001). Bcl-2 Is a Useful Prognostic Marker in Dukes' B Colon Cancer. Ann. Surg. Oncol.
8: 533-537
[Abstract][Full Text]
Schrag, D., Cramer, L. D., Bach, P. B., Begg, C. B.
(2001). Age and Adjuvant Chemotherapy Use After Surgery for Stage III Colon Cancer. JNCI J Natl Cancer Inst
93: 850-857
[Abstract][Full Text]
Previous
